Allergy Therapeutics (LON:AGY) Releases Earnings Results

Allergy Therapeutics (LON:AGY) released its earnings results on Tuesday. The company reported GBX (0.38) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a positive return on equity of 227.10% and a negative net margin of 72.91%.The company had revenue of GBX 3,628 million for the quarter.

Allergy Therapeutics Price Performance

Shares of LON AGY remained flat at GBX 10.30 during trading hours on Thursday. The stock had a trading volume of 71,346 shares, compared to its average volume of 280,355. The stock has a market capitalization of £652.25 million, a PE ratio of -12.26, a P/E/G ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of -213.13, a current ratio of 1.28 and a quick ratio of 1.48. Allergy Therapeutics has a 12 month low of GBX 5 and a 12 month high of GBX 12.10. The firm’s fifty day moving average price is GBX 10.96 and its 200 day moving average price is GBX 10.04.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.